Clinical Trials Logo
  1. Home
  2. Stargardt Disease
  3. NCT04239625

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Stargardt Disease Clinical Trial

Official title:
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease

Clinical Trial Summary

The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04239625
Study type Interventional
Source Alkeus Pharmaceuticals, Inc.
Contact
Status Enrolling by invitation
Phase Phase 2
Start date December 20, 2019
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01676766 - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease N/A
Enrolling by invitation NCT06048185 - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Recruiting NCT05674058 - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Recruiting NCT06435000 - An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Completed NCT04909398 - Pupil Dynamics and Color Vision for the Detection of Eye Diseases N/A
Completed NCT02255981 - Efficacy of Acupuncture in Macular Diseases N/A
Completed NCT05266014 - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease Phase 1/Phase 2
Recruiting NCT06467344 - Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR) Phase 1/Phase 2
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Recruiting NCT06445322 - Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
Completed NCT05417126 - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease Phase 2
Completed NCT03772665 - Safety and Efficacy of Emixustat in Stargardt Disease Phase 3
Terminated NCT02875704 - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Completed NCT03033108 - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Phase 2
Recruiting NCT03011541 - Stem Cell Ophthalmology Treatment Study II N/A
Completed NCT02410122 - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Recruiting NCT05956626 - Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease Phase 1/Phase 2
Recruiting NCT02402660 - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2
Completed NCT01977846 - A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies